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Endometrial cancer (EC) is the most common malignancy 
of the female genital tract in the developed countries [1]. In 
Poland, EC incidence increased from 3.496 to 5.251 between 
2000 and 2011, with 5.251 new cases were diagnosed in 
2011 alone [2], and this upward trend is expected to conti- 
nue  [3]. There are two types of endometrial cancer: estro-
gen-related type I (approximately 80% of the cases) and un-
related to estrogen type II. Type I includes adenocarcinomas 
which grow slowly, have better prognosis, superficially infil-
trate the myometrium, originate from endometrial hyperpla-
sia without atypia, and occur before and after menopause. 
The most common type I mutations include PTEN, KRAS and 
microsatellite instability. Type II is represented by serous, mu-
cinous, clear-cell carcinomas, with aggressive behavior asso- 
ciated with poor prognosis, high risk of distant metastases 
at diagnosis, deeper infiltration of the uterine muscle, often 
to serosa, originating from the atrophic endometrium, and 
typically presenting after menopause. The most common 
type II mutations include TP53, HER-2 and P16 [1]. 
Prognostic factors in EC include the presence of estro-
gen receptors (ER) and progesterone receptors (PR), as well 
as  HER2 overexpression. PR and ER are markers of good 
prognosis [4, 5]. Their absence indicates poorer prognosis, 
an unfavorable histological type (such as clear-cell or serous 
carcinoma), higher histological grade, more frequent me-
tastasis to the lymph nodes, and higher clinical staging at 
diagnosis [6, 7]. HER2 overexpression implies poor progno-
sis, higher histological grade and clinical staging, and shorter 
survival [8, 9, 10]. Similarly shorter survival was observed 
in patients with breast cancer with HER2 overexpression 
[11, 12]. Endometrial carcinoma with simultaneous absence 
of ER and PR expression as well as HER2 is marked as triple 
negative type (ER-, PR-, HER-2 -). 
Numerous authors have described the relation between 
ER, PR and HER-2 expression and clinico-pathological fac-
tors, as well as prognosis in endometrial cancer. However, 
to the best of our knowledge, only 4 papers have dealt with 
triple negative EC [13–16].
The triple negative phenotype was first described in 
breast cancer. Triple negative carcinoma is associated with 
a higher risk of metastasis and poor prognosis [17]. Simi-
larly to 12–17% of triple negative breast cancer cases, the 
triple negative phenotype is observed in approximately 
15–20.7% of EC patients [13, 14]. It is related to more fre-
quent metastases to the lymph nodes, deeper myometrial 
invasion, unfavorable histological type, higher histological 
grade and clinical staging, and shorter survival [14]. Due to 
poor prognosis, the search for new treatment options for 
EC continues [13]. 
The triple negative phenotype is also found in 15.5% of 
ovarian cancers [18]. Interestingly,  the percentage of triple 
negative ovarian, endometrial and breast cancers is similar, 
which may indicate similar pathogenesis.
In the group of triple negative breast cancers, the 
BRCA-1 mutation occurs in 10% of the cases [17]. On the 
other hand, 90% of BRCA-dependent tumors are triple nega-
tive.  Moreover, similarly to the BRCA-1 mutation, the PTEN 
mutation, detected in 30–80% of EC cases, sensitizes cancer 
cells to the therapy with PARP-1 inhibitors [19–21]. High 
activity of PARP-1 is observed at the time of genome instabil-
ity [22]. A high level of the PARP-1 expression was observed 
in BRCA-1-dependent breast cancers. Cancer cells which 
are constitutively deprived of one DNA repair mechanism 
have been found to reveal overexpression of PARP-1[23], 
which has become a rationale for clinical studies on the 
PARP-1 inhibitor in BRCA-dependent breast cancers [24, 25]. 
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PTEN is a suppressor gene located on the long arm of 
chromosome 10 (locus 10q23.31) which encodes phosphati-
dylinositol-3 ,4, 5-trisphosphate phosphatase, a protein 
taking part in the regulation of the phosphatidylinositol 
3-kinase (PI3-K)/AKT pathway. The activation of this pathway 
impacts cell growth and survival. Mutation in the PTEN gene, 
which is usually caused by the mutation of both its alleles, 
leads to the loss of the suppressing effect of an encoded pro-
tein on the PI3-K/AKT pathway, thus disturbing the cell-divi- 
sion cycle and  preventing abnormal cell apoptosis  [26]. 
The PTEN protein is of a considerable diagnostic value in EC 
prognosis [27]. The PTEN gene mutation is associated with 
positive prognostic factors such as a favorable histological 
type, lower histological grade, absence of myometrial inva-
sion, and lower clinical staging [28]. PTEN mutations are 
related to tumor response to chemotherapy. Apart from its 
direct cancer-fighting property due to the HER-2 receptor 
inhibition, trastuzumab acts indirectly through activation of 
the PTEN protein, thus restraining the PI3-K/AKT pathway 
and causing apoptosis. The mutation of PTEN which prevents 
the expression of the protein can provoke the resistance 
of HER-positive cells to trastuzumab [29]. Abnormal PTEN 
expression leads to an increased activity of the mTOR pro-
tein kinase, thus improving the sensitivity of these cells to 
chemotherapy with mTOR inhibitors [30].
Clinical trials are aimed at individualizing therapy. The 
purpose of a targeted therapy is to reduce the adverse effects 
of cancer-fighting drugs by destroying tumor cells directly, 
while saving the healthy ones. Therefore, advanced clinical 
studies are conducted on PARP-1 inhibitors and on drugs 
which can block the mTOR and PI3K/AKT pathways. The 
PARP-1 expression in breast cancers indicates its varied 
activity in individual histological types of this cancer [23]. 
Noteworthy, PARP inhibitors are present in the treatment of 
all types of triple negative tumors. Considering their similar 
pathogenesis and the equal role of DNA repair pathways, 
we can expect similar effects in their treatment. What is also 
important is an equal role of the PARP mutation in breast and 
ovarian cancers, as well as of the PTEN mutation in endome-
trial cancer. The drugs expected to be used in the therapy of 
triple negative carcinomas are responsible for inhibiting the 
PARP protein or the mTOR and PI3K-AKT pathways. The latest 
research has found that the activity of PI3K/AKT pathway is 
absent in triple negative endometrial cancers [31].   
Data on the expression levels of receptors which are 
prognostic factors in triple negative endometrial cancers 
are limited. The existing studies have reported significantly 
higher CD151 expression in triple negative endometrial 
cancer as compared to other histological types. Increased 
CD151 expression is the basis for worse prognosis [15]. 
Likewise, higher CD151 expression in triple negative breast 
cancer is associated with shorter survival time and poorer 
prognosis [32].
A study examined the relation between tumor-related 
macrophages and the triple negative phenomenon in the 
endometrial cancer. In comparison to tumors which are not 
burdened with this phenomenon, a considerably higher per-
centage of tumor-related macrophages were found in triple 
negative cancer. Also, a relation between EGFR expression 
and triple negative endometrial cancer was observed [13]. 
The results of research on the role of individual receptor 
expression in triple negative ovarian cancer have not been 
published yet. Noteworthy, triple negative cervical cancer 
has not been described in the literature so far. 
Studies on the triple negative phenomenon continue to 
be conducted. Due to their aggressive character and poor 
prognosis, triple negative cancers are important objects of 
research and may serve as individualized treatment targets. 
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